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Available online 21 May 2016Epithelial-mesenchymal transition (EMT) and the mesenchymal-epithelial transition (MET) are processes re-
quired for embryo organogenesis. Liver develops from the epithelial foregut endoderm fromwhich the liver pro-
genitors, hepatoblasts, are speciﬁed. The migrating hepatoblasts acquire a mesenchymal phenotype to form the
liver bud. Inmid-gestation, hepatoblastsmature into epithelial structures: the hepatocyte cords and biliary ducts.
While EMT has been associated with liver bud formation, nothing is known about its contribution to hepatic
speciﬁcation.We previously established an efﬁcient protocol from human embryonic stem cells (hESC) to gener-
ate hepatic cells (Hep cells) resembling the hepatoblasts expressing alpha-fetoprotein (AFP) and albumin (ALB).
Here we show that Hep cells express both epithelial (EpCAM and E-cadherin) and mesenchymal (vimentin and
SNAI-1) markers. Similar epithelial and mesenchymal hepatoblasts were identiﬁed in human and mouse fetal
livers, suggesting a conserved interspecies phenotype. Knock-down experiments demonstrated the importance
of SNAI-1 in Hep cell hepatic speciﬁcation. Moreover, ChIP assays revealed direct binding of SNAI-1 in the pro-
moters of AFP and ALB genes consistent with its transcriptional activator function in hepatic speciﬁcation. Alto-
gether, our hESC-derived Hep cell cultures reveal the dual mesenchymal and epithelial phenotype of
hepatoblast-like cells and support the unexpected transcriptional activator role of SNAI-1 in hepatic speciﬁcation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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SNAI-11. Introduction
The epithelial-mesenchymal transition (EMT) deﬁnes a series of or-
chestrated events during which epithelial cells lose the majority of epi-
thelial characteristics and acquire properties typical of mesenchymal
cells (Thiery and Sleeman, 2006). This process requires complex chang-
es in the architecture and transcriptional program of the cell, which are
tightly regulated by the transcription factor SNAI (Cano et al., 2000). The
analogous but reverse mechanism gives mesenchymal cell characteris-
tics of an epithelial cell, which is deﬁned as a mesenchymal-epithelial
transition (MET). EMT and MET are two major processes associated
with embryogenesis from the blastula formation (Rossant and Tam,
2009; Stephenson et al., 2010; Takaoka and Hamada, 2012), gastrula-
tion during which the embryonic epithelium gives rise to the threeep cells, hESC-derived hepatic
platelet-derived growth factor
main receptor; SNAI-1, Snail-1;
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CAM, epithelial cell adhesion
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. This is an open access article undergerm layers and subsequent organogenesis (Dressler, 2009; Nieto,
2001; Schluter and Margolis, 2009). More speciﬁcally, organogenesis
of endoderm derived-tissues including the pancreas and liver requires
EMT and MET (Lemaigre, 2009). For example, liver bud formation re-
sults from delamination of pseudostratiﬁed hepatic foregut endoderm
cells through an EMT. Hepatic endoderm cells are known as
hepatoblasts, and are the fetal progenitors for hepatocytes and
cholangiocytes of the adult liver. As the fetal liver grows, mesenchymal
hepatoblasts proliferate and differentiate into epithelial hepatocytes or
biliary duct cells (Gordillo et al., 2015). Observations of developing
fetal livers suggested that MET accompanies the differentiation of
human and mouse liver progenitors to hepatocytes and cholangiocytes
(Bort et al., 2006; Li et al., 2011; Vestentoft et al., 2011).
Here we asked whether the EMT process is recapitulated during
early liver speciﬁcation from human embryonic stem cells (hESCs),
and whether EMT directly controls liver speciﬁcation. We previously
identiﬁed two types of cells generated during differentiation of hESCs
toward the hepatic lineage (Goldman et al., 2013): the KDR (VEGFR2/
FLK-1)-expressing hepatic progenitors and the hepatoblast-like hepatic
cells (Hep cells) that are negative for KDR. We characterized the devel-
oping Hep cells as having a mixed phenotype since they express both
epithelial (E-cadherin, EpCAM) and mesenchymal (Vimentin, SNAI-1)
markers. Most interestingly, in contrary to its conventional role inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the notion that SNAI-1 acts autonomously as a transcriptional activator
by instructing hepatic cell fate of the developing Hep cells.2. Material and methods
2.1. Human hepatic differentiation and cell sorting
Human ESCs (HES2) were differentiated into hepatic cells following
embryoid body formation in Serum Free Differentiation (SFD) medium
with 1 mM Ascorbic Acid, 4 × 10−4 monothioglycerol, 2 mM glutamine
and BMP4 (10 ng/ml) (Goldman et al., 2013). At day 1 of differentiation,
medium was changed to SFD complemented with 1 mM Ascorbic Acid,
4 × 10−4 monothioglycerol, 2 mM glutamine, BMP4 (0.5 ng/ml), bFGF
(2.5 ng/ml) and a high dose of Activin-A (100 ng/ml). At day 4 of differ-
entiation the medium was changed to SFD complemented with 1 mM
Ascorbic Acid, 4 × 10−4 monothioglycerol, 2 mM glutamine, VEGF
(10 ng/ml), bFGF (2.5 ng/ml) and Activin-A (100 ng/ml) (Goldman et
al., 2013). At day 5 of differentiation, CXCR4+cKIT+KDR-PDGFRα-en-
doderm cells were puriﬁed by FACS using an Aria cell sorter (BD Biosci-
ence, CA) and cultured in hepatic media as previously deﬁned (Han et
al., 2011). At days 9, 12 and 17 of differentiation KDR-CD31-Hep cells
were puriﬁed by FACS and either cultured in hepatic media as previous-
ly deﬁned or analyzed by ﬂow cytometry, real time qPCR or
immunostaining.2.2. Flow cytometry analyses
Cells were trypsinized and resuspended in PBS1X/BSA 0.3%. For cell
surface protein cells were stained with speciﬁc antibodies listed in Sup-
plemental Table 1 for 20min at room temperature and analyzed using a
LSRII ﬂow cytometer (Becton Dickinson).2.3. Quantitative real time PCR analyses
Total RNA was extracted using the RNeasy micro kit (Qiagen). Re-
verse transcriptionwas performed with the Super Script-III First-strand
Synthesis Systemkit (Invitrogen). qPCRwas performed using the Roche
SYBR Green master mix and analyzed with the Roche system LC480.
Primers sequences used are listed in supplemental Table 2.2.4. Immunostaining
Cells were ﬁxed with 4% paraformaldehyde for 10min at room tem-
perature, permeabilized in 0.3% triton for 10min and then blockedwith
the protein block serum-free kit from DAKO. Incubation with primary
(overnight, 4C) and secondary antibodies (1 h, room temperature)
(listed in Table 1) was performed in PBS1X/BSA 0.3%. DAPI was used
to stain the cell nuclei. Images of immunostained cells were acquired
using a Fluorescent inverted microscope (Leica).2.5. Immunohistochemistry
Human fetal livers, 7–22weeks old, or E9.5 mouse embryos or E13.5
mouse fetal livers were ﬁxed overnight with 4% paraformaldehyde,
dehydrated with 30% sucrose and embedded in OCT. 7-μm sections
were permeabilized with 0.3% Triton X-100 for 10min at room temper-
ature and then blocked for 20min with 2% donkey serum at room tem-
perature. Sections were immunostained at 4 °C overnight with primary
antibodies (listed in supplemental Table 1) and then incubated for 1 h at
room temperature with secondary antibodies (listed in supplemental
Table 1) and counterstained with DAPI. A ﬂuorescent confocal micro-
scope (Leica) was used to visualize sections.2.6. siRNA assays
Pools of four siRNA against SNAI-1 (L-017386-00-0005), SNAI-2 (L-
017386-00-0005) or control non-target (D-001810-10-05) were pur-
chased from Thermo Scientiﬁc. siRNA transfection was performed at
day 10 and 12 of differentiation on puriﬁed Hep cells. Brieﬂy, according
to the manufacturer's protocol, 5 μM of each siRNA pool were incubated
with OptiMEM for 5 min at room temperature. In parallel, 2 μl of
Dharmafect transfection reagent 1 (Thermo T2005-01) was incubated
with OptiMEM for 5 min at room temperature. The two reactions were
then mixed together for 20 min at room temperature and then mixed
with the hepatic culture media in the absence of antibiotics onto the
cells. 24 h prior to transfection, cells were cultured in hepatic medium
without antibiotics. The following day of each transfection, the medium
was changed with regular hepatic medium without antibiotics.
2.7. Chromatin immunoprecipitation (ChIP)
ChIPwas performed as previously described (Lien et al., 2011). Brief-
ly, at day 9 of differentiation, hESC-derived Hep cells were ﬁxed 10min
with 1% formaldehyde at room temperature. Nuclei where isolated and
subjected to 30 cycles of sonication in the presence of Triton X-100
using Diagenode Bioruptor (30 s on, 30 s off at 4C). Sonicated chromatin
from approximately nine 35 mm plates where incubated rotating over-
night with 4 μl of two different antibodies against SNAI (1 and 2)
(SNAI1/2 abcam Ab78105 or Snail1 Cell Signaling 3879S) or non-specif-
ic IgGs (IgG rabbit polyclonal ChIP Grade, ab171870) in DNA LoBind
Eppendorf tubes at 4C. 10% of the sample was saved as input. Immuno-
precipitation was performed by adding Protein G (Dynabeads 10003D,
Life Technologies) for an additional 6 h at 4C. Beads where washed
with Low Salt, High Salt, LiCl and TE buffers for 10 min each, after
which the chromatin was eluted in 100 μl of 1% SDS buffer. Inputs and
eluted chromatin were incubated overnight at 65C to revert the
crosslinking. Samples were then treated with RNaseA and Proteinase
K, and DNA was puriﬁed using Zymogen ChIP DNA Clean and Concen-
trator columns. QPCR was performed with Sybergreen in a Roche
Lightcycler 480. Primers sequences used are listed in supplemental
Table 3. The percentage of input recovery was calculated from the
input signal of each primer in each experiment.
2.8. Statistical analysis
Results are expressed as mean± SD. For each group, at least 3 inde-
pendent experiments were analyzed and different groups were com-
pared using Student's t-test analysis. p b 0.05 was considered
statistically signiﬁcant *, p b 0.05; **, p b 0.01; and ***, p b 0.001.
3. Results
3.1. hESC-derived hepatic cells (Hep cells) are epithelial cells expressing the
mesenchymal markers SNAI and vimentin
As described in our previous work, Hep cells were generated from
hESCs by ﬁrst inducing endoderm formation with a high dose of
Activin-A (Goldman et al., 2013). At day 5 of differentiation, endoderm
cells were puriﬁed by ﬂuorescence-activated cell sorting (FACS) (with
purity N95%) based on the expression of CXCR4 and cKIT and exclusion
of the mesendodermal marker PDGFRα (platelet-derived growth fac-
tor) and the receptor KDR (VEGFR2 or FLK-1) (Goldman et al., 2013).
The puriﬁed endoderm cell population was subsequently differentiated
into Hep cells together with hepatic progenitors expressing KDR
(Goldmanet al., 2013). Both populationswere negative for the endothe-
lial marker CD31 (Goldman et al., 2013). As a ﬁrst approach to investi-
gate whether EMT occurs during hepatic differentiation, Hep cells,
deﬁned as cells negative for both KDR and CD31, were analyzed over
time for expression of mesenchymal and epithelial markers (Fig. 1A).
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patic differentiation was conﬁrmed by alpha-fetoprotein (AFP) expres-
sion as early as day 9 of differentiation, whichwasmaintained until day
17 (Fig. 1B). Detection of albumin (ALB) protein in most puriﬁed KDR-
CD31-Hep cells by day 17 of differentiationwas indicative of further he-
patic maturation (Fig. 1B). The hepatic phenotype and functional char-
acterization of Hep cells was reported in our previous work (Goldman
et al., 2013). In line with a hepatic phenotype, all Hep cells expressed
the epithelial marker EpCAM (epithelial cell adhesion molecule)
(Trzpis et al., 2007) at days 9, 12 and 17 of differentiation (Fig. 1C). In-
terestingly, a subset of Hep cells also expressed themesenchymalmark-
er CD90 (Thy-1) (Delorme et al., 2006) with the percentage of positive
cells varying from 3.2% at day 9 to 15% at later stages of differentiation
(Fig. 1C). Protein expression of two additional mesenchymal markers
SNAI (1 and 2) (Kalluri andWeinberg, 2009) and vimentinwas detected
in all Hep cells (99 and 95% respectively of total Hep cells) following pu-
riﬁcation at day 9 and further culture for one day (Fig. 1D). EpCAM pro-
tein in virtually all Hep cells (98% of total Hep cells) was also conﬁrmed
in this assay (Fig. 1D), indicating that Hep cells co-express both epithe-
lial andmesenchymalmarkers at day 9 of differentiation as they initiate
hepatic speciﬁcation.
Concomitant detection of bothmesenchymal and epithelial markers
in Hep cells was validated by quantitative real time PCR (qPCR) (Fig.
1E). The epithelial EpCAM and E-cadherin (CDH1) transcript levels inFig. 1.Developing hESC-derived Hep cells express both epithelial andmesenchymal markers. (A
markers AFP and ALB on Hep cells puriﬁed and cytospun at days 9, 12 and 17 of differentiatio
differentiation (one representative experiment out of 2, n= 2 independent experiments). (D)
and the epithelial marker EpCAM in Hep cells puriﬁed at day 9 of differentiation and cultured
cells for each marker (vimentin, EpCAM and SNAI-1/2) among the total number of Hep
differentiations. (E) Relative transcript levels in Hep cells puriﬁed at days 9, 12 and 17 of dif
black columns) was set to 1 and Huvecs (white columns) were used as negative control. Purp
SD (n= 3 independent experiments). ND: not detectable (cycle number above 40).puriﬁed Hep cells were as high as those in endoderm cells regardless
of the time of differentiation, and signiﬁcantly much higher than mea-
sured in Huvec cells that served as negative control for both epithelial
and mesenchymal phenotype. Transcript levels for the mesenchymal
marker vimentin remained high following hepatic speciﬁcation of Hep
cells, while undetectable in Huvec cells. Interestingly, themesenchymal
markers SNAI-1 and SNAI-2were expressed in Hep cells in an opposite
pattern over time, with decreasing levels of SNAI-1 and increasing levels
of SNAI-2 transcripts as Hep cells specify and mature (Fig. 1E), suggest-
ing their distinct roles in liver differentiation. Speciﬁcally, detection of
high levels of SNAI-1 in endoderm cells and day 9 Hep cells suggested
a role for SNAI-1 in an early hepatic fate decision of endoderm. Altogeth-
er, protein and transcript level analyses of mesenchymal and epithelial
markers deﬁned developing hESC-derived Hep cells as cells with dual
mesenchymal and epithelial characteristics.
3.2. Identiﬁcation of mesenchymal and epithelial hepatoblasts in human
and mouse fetal livers
To examine whether the dual mesenchymal and epithelial features
of Hep cells are relevant to human fetal liver development and con-
served in the mouse fetal liver in vivo, we performed immunostaining
for HNF4α or ALB to identify hepatoblasts together with SNAI (1 and
2) in human and murine developing livers (Fig. 2). A small number of) Timeline of hepatic differentiation of hESC and analyses. (B) Immunostaining for hepatic
n (×200). (C) Flow cytometry analysis of Hep cells (KDR-CD31-) at days 9, 12 and 17 of
Immunostaining in the dish for the mesenchymal markers vimentin and SNAI (1 and 2)
for one more day (×200). Graphs indicate the means ± SD of the percentage of positive
cells. Three different ﬁelds for each staining were examined for n = 3 independent
ferentiation. Gene expression from day 5 CXCR4 + cKIT + PDGFRα-KDR-cells (End d5,
le columns represent Hep cells at different time points. Data are represented as mean ±
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HNF4α+ cells) or ALB and SNAI were identiﬁed in 7 weeks old
human fetal livers (Fig. 2A, arrows). Few HNF4α+SNAI+ hepatoblasts
(2% cells among HNF4α+ cells) were also detected later in 22 weeks
old human fetal liver samples (Fig. 2A, arrows) as well as in the liver
bud of E9.5 mouse embryos and mouse fetal livers at E13.5 (Fig. 2B, ar-
rows). No speciﬁc anatomical location of the HNF4α+SNAI+
hepatoblasts within the human or murine fetal liver was identiﬁed. Al-
together, a small subset of hepatoblasts positive for SNAI was detected
in human and mouse fetal livers, suggesting that similar mesenchymal
hepatoblasts, as observed in hESC-derived Hep cells, are relevant to
human and mouse fetal liver development.
3.3. SNAI-1 controls hepatic speciﬁcation in a cell autonomous fashion in
developing hESC-derived Hep cells
Given the transient expression of SNAI-1 in endoderm cells and in
day 9 Hep cells as they acquire AFP expression (Fig. 1), we investigated
the function of SNAI-1 in instructing early hepatic speciﬁcation of Hep
cells. SNAI-1 expression was knocked-down using a pool of four siRNAs
against SNAI-1 in Hep cells puriﬁed at day 9 and further cultured until
day 13 (Fig. 3A). Hep cells were treated with SNAI-1 siRNAs at day 10
and day 12, and their hepatic fatewas analyzed at day 13. SNAI-1 siRNAs
reduced SNAI-1 transcript levels by 50% (Fig. 3B) and resulted in 75% re-
duction of levels of both hepatic markers AFP and ALB when compared
to scrambled siRNA-treated cells (Fig. 3B, black columns for scrambled
siRNA versus grey columns for SNAI-1 siRNAs). However, transcriptFig. 2. Identiﬁcation of mesenchymal and epithelial hepatoblasts in human and mouse fetal liv
7 weeks old human fetal livers (upper panels) or 22 weeks old human fetal livers (lower pan
among the total number of HNF4α+ hepatoblast cells. (B) Co-immunostaining for HNF4α anlevels of the epithelial marker E-cadherin (CDH1) and the transcription
factor regulating endoderm hepatic speciﬁcation, the hepatocyte nucle-
ar factor 4 α (HNF4α), were not altered by SNAI-1 knock-down, most
likely because their expression was induced prior to the knock-down
assay (Fig. 1E). These results suggested that SNAI-1 is not required for
the maintenance of CDH1 and HNF4α expression. The role of SNAI-1
on hepatic speciﬁcationwas conﬁrmed at theAFP protein level, as virtu-
ally all Hep cells lost AFP expressionwhileHNF4α expressionwasmain-
tained following SNAI-1 knock-down (Fig. 3C). Altogether, SNAI-1
knock-down assays indicate that SNAI-1 induces hepatic marker ex-
pression in early committed Hep cells without modifying the epithelial
phenotype of Hep cells that was also observed in culture (not shown).
Curiously, SNAI-1 siRNAs also decreased transcript levels of SNAI-2 by
50% (Fig. 3B). To thus determine whether SNAI-2 knock-down alters
AFP and ALB expression, Hep cells were treated with a pool of SNAI-2
siRNAs. Similarly, siRNAs against SNAI-2 reduced both SNAI-2 (by 75%)
and SNAI-1 (by 50%) transcript levels (Fig. 3D), and levels of CDH1 and
HNF4α were not altered. Although the presence of SNAI-2 siRNAs led
to a 50% decrease of SNAI-1 levels, there was no synergistic decrease
of AFP and ALB levels but rather a milder diminution of these hepatic
genes (by 25% versus 75% in the presence of SNAI-1 siRNAs), supporting
the notion that SNAI-1 and SNAI-2 have opposite effects on AFP and ALB
expressions. Indeed, SNAI-1 knock-down in the presence of SNAI-1
siRNAs completely abrogated AFP protein levels (Fig. 3C), while SNAI-
2 knock-down in the presence of SNAI-2 siRNAs partially diminished
them (Fig. 3E). Altogether, the SNAI-1 and SNAI-2 knock-down assays
indicated that, whether each other regulation is mediated by siRNAers. (A) Co-immunostaining for HNF4α and SNAI (1 and 2) or ALB and SNAI (1 and 2) of
els) (×200). The graph indicates the means ± SD of the percentage of SNAI-1/2+ cells
d SNAI (1 and 2) of mouse E9.5 liver bud and E13.5 fetal liver (×200).
Fig. 3. SNAI-1 regulates positively hepatic speciﬁcation of Hep cells. (A) Timeline of siRNA transfection and analyses of puriﬁed Hep cells. (B) Relative transcript levels at day 13 of
differentiation following SNAI-1 knock-down assays (n= 3 independent experiments). (C) Co-immunostaining for HNF4α and AFP or Caspase 3 following SNAI-1 knock-down assays.
(D) Relative transcript levels at day 13 of differentiation following SNAI-2 knock-down assays (n = 3 independent experiments). (E) Co-immunostaining for HNF4α and AFP or
Caspase 3 DAPI following SNAI-2 knock-down assays.
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itive regulator of hepatic speciﬁcation.
As EMT has been reported to confer resistance to the apoptotic ef-
fects of transforming growth factor beta in fetal rat hepatocytes
(Valdes et al., 2002), we examined Hep cell apoptosis upon SNAI
knock-down assays (Fig. 3C and E) by caspase 3 immunostaining. Nei-
ther of the siRNAs against SNAI-1 or SNAI-2 led to an increase of Hep
cell apoptosis, indicating that SNAI knock-downs did not alter cell apo-
ptosis that could have indirectly affected hepatic fate decision.
Immuno-precipitation (ChIP) assays of day 9 Hep cells using 2 sepa-
rate antibodies recognizing both SNAI-1 and 2 demonstrated further
that SNAI (1 and/or 2) binds directly to two separate upstream promot-
er regions of AFP and ALB genes as well as of CDH1 gene previously re-
ported to be transcriptionally repressed by SNAI-1. These data suggest
a direct transcriptional activator function of SNAI in hepatic speciﬁca-
tion of developing Hep cells in a cell autonomous manner (Fig. 4A, B).
4. Discussions and conclusion
The zinc-ﬁnger transcription factors SNAI (1 and 2) are convention-
ally reported to induce EMT when expressed in epithelial cells duringorganogenesis (Cano et al., 2000) by maintaining the mesenchymal
phenotype and directly repressing epithelial gene expression (Thiery
et al., 2009). However, recent studies provided evidence that SNAI fac-
tors paradoxically enhance reprogramming of mesenchymal ﬁbroblasts
to induced pluripotent stem cells (iPSCs) characterized with an epithe-
lial phenotype (Gingold et al., 2014; Unternaehrer et al., 2014). In this
system, SNAI-1 together with the pluripotent factor NANOG coopera-
tively function as transcriptional activators of pluripotency-associated
genes (Gingold et al., 2014). The transitioning pre-iPSCs express both
the mesenchymal marker SNAI-1 and the epithelial marker E-cadherin,
and are thus reminiscent of the developing hESC-derived Hep cells with
dual mesenchymal and epithelial characteristics. The impact of SNAI-1
in reprogramming mouse ﬁbroblasts to epithelial iPSCs introduced the
notion that SNAI-1 can paradoxically instructs epithelial cell fate. Here,
we discovered a similar function of SNAI-1 as a transcriptional activator
instructing hepatic speciﬁcation of hESC-derived Hep cells.
Interestingly, in contrast to the common roles of SNAI-1 and 2 in
repressing E-cadherin mediated EMT, SNAI-1 is the only SNAI factor
that is expressed in endoderm andHep cells, and that instructs positive-
ly hepatic cell fate. The unique function of SNAI-1 compared to SNAI-2
was also noted during the cell reprogramming process, in which solely
Fig. 4. SNAI-1/2 binds to promoter areas of hepatic genes. (A,B) ChIP-qPCR assays using
two different antibodies: (A) Cell Signaling and (B) Abcam, shows the binding of the
transcription factor SNAI-1/2 to upstream sequences of ALB and AFP genes in puriﬁed
day 9 Hep cells. Note that the percentage of recovery in (A) is higher than in (B). As
negative control the open reading frame of the β-Actin (ACTB) gene and the promoter of
the non-hepatic gene Atoh1 are shown. The binding of SNAI-1/2 to human E-Cadherin
(CDH1) is shown as a positive control. Diagrams in the bottom panel show the ampliﬁed
regions for each gene (red). Each chart is representative of 3 independent differentiations.
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reprogramming (Gingold et al., 2014). The differential function of
SNAI factors is clearly shown by the analysis of knock-outmice. Deletion
of SNAI-1 causes embryonic lethality due to gastrulation defects (Carver
et al., 2001), while mice with SNAI-2 deletion are viable and show only
postnatal defects (Parent et al., 2010; Perez-Losada et al., 2002).
The hESC-derived Hep cell differentiation cultures described in this
manuscript constitute a dynamic in vitro platform recapitulating the
transient development of hepatoblasts with dual mesenchymal and ep-
ithelial phenotype as previously observed in E11.5 mouse fetal livers
with the vast majority of hepatoblasts expressing vimentin and AFP
(Li et al., 2011). Speciﬁc expression of SNAI in a much smaller subset
of hHNF4α+hepatoblasts in human andmurine fetal liversmay repre-
sent for instance a small progenitor pool that persists in adult either to
play a role in homeostatic hepatocyte renewal as deﬁned as axin+
cells within the adult central vein areas (Wang et al., 2015) or to beactivated to becomemesenchymal-epithelial oval cellswithin theportal
vein areas when the liver is injured (Yovchev et al., 2008).
In conclusion, this study reveals a unique function of the EMT factor
SNAI-1 in promoting hepatic cell fate in differentiating human Hep cells
derived from hESC cultures. As Hep cells differentiate from endoderm
cells, they express both epithelial (E-cadherin, EpCAM) and mesenchy-
mal (Vimentin, SNAI-1) markers. In contrast to its conventional role in
promoting mesenchymal phenotype during EMT, our work introduces
a novel role for SNAI-1 as a transcriptional activator to instruct cell au-
tonomously hepatic cell fate in differentiating Hep cells.
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